MIMEDX Announces Launch of AXIOFILL™
MARIETTA, Ga., Sept. 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the launch of AXIOFILL™, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue.
- MARIETTA, Ga., Sept. 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), a transformational placental biologics company, today announced the launch of AXIOFILL, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue.
- AXIOFILL is the first and only human placental-derived particulate product available for Surgical Recovery procedures.
- AXIOFILL provides a cost-effective human collagen scaffold that is conducive for use in large, complex wounds and those of irregular geometries.
- The launch of AXIOFILL is particularly significant for MIMEDX, said Rohit Kashyap, Ph.D., MIMEDX President, Wound Care & Surgical.